Traduction de «clinical development » (Anglais → Français) :

pre-clinical trial [ preclinical study | nonclinical study | pre-clinical development ]

creation of opinions in clinical psychology | development of opinions in clinical psychology | creation of clinical psychological opinions | formation of opinions in clinical psychology

Definition: This block contains a wide variety of disorders that differ in severity and clinical form but that are all attributable to the use of one or more psychoactive substances, which may or may not have been medically prescribed. The third character of the code identifies the substance involved, and the fourth character specifies the clinical state. The codes should be used, as required, for each substance specified, but it should be noted that not all fourth character codes are applicable to all substances. Identification of the psychoactive substance should be based on as many sources of information as possible. These include sel ...[+++]f-report data, analysis of blood and other body fluids, characteristic physical and psychological symptoms, clinical signs and behaviour, and other evidence such as a drug being in the patient's possession or reports from informed third parties. Many drug users take more than one type of psychoactive substance. The main diagnosis should be classified, whenever possible, according to the substance or class of substances that has caused or contributed most to the presenting clinical syndrome. Other diagnoses should be coded when other psychoactive substances have been taken in intoxicating amounts (common fourth character .0) or to the extent of causing harm (common fourth character .1), dependence (common fourth character .2) or other disorders (common fourth character .3-.9). Only in cases in which patterns of psychoactive substance-taking are chaotic and indiscriminate, or in which the contributions of different psychoactive substances are inextricably mixed, should the diagnosis of disorders resulting from multiple drug use (F19.-) be used. | Modifiers The following fourth-character subdivisions are for use with categories F10-F19: Code Title .0 Acute intoxication A condition that follows the administration of a psychoactive substance resulting in disturbances in level of consciousness, cognition, perception, affect or behaviour, o ...

Ottawa Conference on Assessing Clinical Competence [ Ottawa Conference on Newer Developments in Assessing Clinical Competence | The Second Ottawa Conference on Assessing Clinical Competence | The Second Ottawa Conference on Newer Developments in Assessing Clinical Competence | The First Ottawa Conference on Asses ]

animal trials | development phases for pharmaceutical drugs | clinical phase | pharmaceutical drug development

advanced nurse manager | clinical academic nurse specialist | advanced nurse practitioner | staff development manager

multicenter trial | multicentre trial | multicenter clinical trial | multicentre clinical trial | multicentered trial | multicentered clinical trial | multicenter study | multicentre study | multicenter clinical study | multicentre clinical study | multicentered study | multicentered clinical study

Clinical Trial Coordination and Development Division

community legal clinic | legal clinic | community legal service | community legal services clinic | legal services clinic

Pre-clinical and/or clinical development of designated orphan drugs will be supported.

[16] The rare disease topics in the 2012 and 2013 FP7 Health Calls were: 'Support for international rare disease research; Clinical utility of –omics for better diagnosis of rare diseases; Databases, biobanks and clinical ‘bio-informatics’ hub for rare diseases; Preclinical and clinical development of orphan drugs; Observational trials in rare diseases; Best practice and knowledge sharing in clinical management of rare diseases (2012) and Development of imaging technologies for therapeutic interventions in rare diseases; New methodologies for clinical trials for small population groups (2013).

Since the objectives of this Decision, namely to contribute to the reduction of the social and economic burden of poverty-related diseases in developing countries, and in particular in sub-Saharan Africa, by accelerating the clinical development of effective, safe, accessible, suitable and affordable medical interventions for poverty-related diseases, cannot be sufficiently achieved by the Member States due to the lack of necessary critical mass to be achieved, both in human and financial terms, and can therefore, by reason of the scale of the action, be better achieved at Union level, the Union may adopt measures, in accordance with the ...[+++] principle of subsidiarity as set out in Article 5 of the Treaty on European Union.

EDCTP2 shall contribute to the reduction of the social and economic burden of poverty-related diseases in developing countries, in particular in sub-Saharan Africa, by accelerating the clinical development of effective, safe, accessible, suitable and affordable medical interventions (1) for poverty-related diseases, in partnership with sub-Saharan Africa.